Raising Cash? American Home Cutting Immunex Stake
But American Home denied that the move, which could cut its stake to 43% from 55%, was aimed at raising money to pay for rising costs to settle
American Home said last month it may have to boost its reserves, currently about $3.3 billion, by "less than $5 billion" to pay for litigation from two diet drugs that were withdrawn in 1997. Analysts speculated the company could need as much as $3 billion more.
Lowell Weiner, a company spokesman, says the company is flush with cash. He says American Home will use the money from the Immunex stake sale to boost research and development and to fund other corporate purposes. The company recently got $1.8 billion as a merger breakup fee from its broken deal with Warner-Lambert, and an added $3.8 billion from the sale of its agrochemicals division."We don't need this cash to handle litigation," Weiner says. "We're confident the cost is manageable from existing resources." He says the company simply wanted to "monetize" stock gains from Immunex. American Home said it plans to sell up to 50 million Immunex shares in a secondary offering, "market conditions permitting." Separately, Immunex said it filed to sell up to 20 million new Immunex shares.
But Perhaps Less Than a Full HouseAmerican Home inherited its stake in Immunex in 1994 when it bought American Cyanamid, an agrochemical and drug company. That purchase turned out to be hugely successful for American Home, allowing it to benefit from Immunex's rapid stock gains and giving it access to Enbrel, a fast-growing arthritis drug that both companies sell. After the stock sale, American Home will continue to market Enbrel, the company said. The move comes at a time when other drug companies are boosting their stakes in biotech companies, looking to bolster their product offerings as in-house research-and-development operations become less productive. Genentech (DNA), for instance, is 59% held by Roche, while Chiron (CHIR) is about 44% held by Novartis (NVS).
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV